AZTA · Azenta, Inc.
AI read · Good for AZTA
The AI's read
The added technology could let Azenta offer more types of DNA synthesis through GENEWIZ and serve more customers. SynPlexity also adds DNA assembly expertise, but Azenta must fit that technology into its business. The agreements call for $32 million to $71 million in planned spending. The exclusive license starts with a 5-year term. Making it perpetual and exclusive can require another $25 million. Without that choice, the product license generally continues as perpetual but non-exclusive. The new tools support expansion, but the spending and license terms limit the benefit.